December 14, 2010 -Cancer Targeted Technology Enters Into A Research and License Option Agreement with Bayer Pharma AG to Advance a Cancer PET Imaging Agent Toward Clinical Trials.
Seattle, Washington, December 14, 2010. Cancer Targeted Technology (CTT), a Seattle-based biotechnology firm focusing on small molecule cancer enzyme inhibitors for the generation of novel diagnostics and therapeutics, today announced that it has signed a Research and License Option Agreement with Bayer Pharma AG, Germany. Under the agreement, CTT will work with Bayer to optimize a novel PET imaging agent based on its unique inhibitor scaffold that recognizes a validated cancer enzyme biomarker. CTT will enhance the chemistry associated with its demonstrated tumor homing scaffold and Bayer will optimize the radiolabeling efforts needed to advance a lead to clinical development. Under the terms of the agreement, CTT will receive R&D funding and if the option is exercised could receive payments on the achievement of development milestones, as well as royalties on sales of products resulting from the collaboration. Financial details of the agreement were not disclosed.
"CTT has focused its initial endeavors on our unique enzyme inhibitors as ideal delivery agents for diagnostic and therapeutic use in cancer" stated Dr. Beatrice Langton-Webster, CTT's Chief Executive Officer. "Particular cancer types desperately need new means of diagnosis that remove ambiguity and offer informed options for the necessity of certain treatment regimens that could involve collateral damage. We also need to better assess the efficacy of treatment choices by clearly locating and monitoring growth of metastatic cancer foci. We have recently shown that our enzyme inhibitors, discovered by our CSO, Dr. Cliff Berkman, are unique in the field of targeting selected cancer types. We are very pleased to have entered into this collaboration with Bayer as they clearly have strong radiochemistry skills and also worldwide clinical and marketing expertise to advance development of a PET imaging agent for cancer", she added. CTT's Chief Scientific Officer and Professor of Chemistry at Washington State University, Dr. Clifford Berkman stated, "Our recent developments in radiolabeling chemistry, along with Bayer's expertise in the area, are ideally suited to rapidly uncover a promising clinical trial candidate."
Cancer Targeted Technology designs and patents small molecular weight enzyme inhibitors with unique and unexploited imaging and drug delivery properties for use in cancer diagnostics and therapeutics.
CONTACT: Dr. Langton-Webster or (425) 806-4801 for more information
April 16, 2010 -Our CEO was recently interviewed by Mr. Bob Crimmons, co-founder of iMedExchange, a social networking site for physicians and is reproduced below. The interview was put on the iMedExcahnge website as a blog for further comment and can be found at iMedExchange.
"As a man approaching middle age, I have to say I listened to Beatrice Langton-Webster, CEO of Cancer Targeted Technology (CTT), with a little extra interest. CTT is developing a PET imaging agent that helps diagnose and monitor early and late-stage cancers; their first product, CTT-54, is aimed at prostate cancer. Incorporated in 2005, with initial patent filings, CTT became fully operational in 2009 when Dr. Langton-Webster took the helm, bringing 25 years of experience in pharmaceutical drug development and commercialization. I asked Bea to share some of the challenges facing early stage pharma companies and what is in store for the future of CTT.
With a little over 5 years of development, clinical trials and FDA approval , CTT has a lot of work ahead but in reality this timing is rapid for this type of diagnostic agent due in part to similarities with another product currently on the market. Bea stated "it is important for Pharmas and Biotechs to understand not only what makes their products better than their competitors, but also what the patient and physician really need and will use." Bea is excited about CTT-54 due to significant benefits it has over existing agents. According to Bea, "CTT-54 targets an important molecular marker in prostate cancer, and will have important advantages over the marketed imaging agent, Prostascint, and other agents in development, including the ability to specifically image abdominal and distal bone disease, the ability to collect better resolution images and the ability to image smaller tumor lesions. For the physician it is important that we develop an agent that has the capabilities to specifically detect minimal disease in multiple locations. For the patient, it is important that we develop a diagnostic with time and cost convenience. We will be able to provide CTT-54 images within a couple of hours with better overall diagnostic accuracy , no associated toxicity and at a cost that is lower than our competitors".
A critical challenge for CTT, at this stage, is understanding how physicians would use this new diagnostic agent. For example, CTT-54 would allow physicians to relatively quickly, easily and safely monitor metastatic disease and the effectiveness of cancer treatment in ways that are not practicable today; whether this new capability would be embraced by physicians and what physicians would need to support it are questions CTT would like to ask physicians.
Relatively speaking, CTT is on a fast track to commercialization but there is still a lot of work to be done, including clinical trials, FDA approval... and some more fund raising. Physicians will play a vital role in all aspects of this work, from product development to monotoring clinical trials and FDA advocacy. Physicians even play an important critical role in fund raising by supporting CTT's market validation claims with venture capital firms and potential strategic partners.
CTT is a paradigm example of the life sciences innovation coming out of iMedExchange's own back yard and we'll watch with interest as Bea shepherds the company through the next phases of the process."